Loading
A radioactive cancer medicine built on a small engineered protein instead of an antibody or a tiny peptide. It is meant to reach deep into a tumour, stay there, and leave the rest of the body quickly.
Radiopharmaceuticals have mostly used small molecules and peptides (PSMA ligands, somatostatin analogues) or whole antibodies. Small binders clear fast but exist for few targets; antibodies bind almost anything but circulate for days and irradiate the bone marrow. Miniprotein radioconjugates use engineered binding proteins of intermediate size to reach targets that small molecules cannot, while still clearing quickly. Aktis Oncology describes its platform as designed to penetrate tumours deeply with long residence time while being rapidly cleared from the rest of the body, and pairs it with the alpha emitter actinium-225.
In November 2026 Aktis listed two clinical programmes, both in phase 1b: AKY-1189 against Nectin-4 (NCT07020117; FDA Fast Track designation in previously treated advanced urothelial cancer) and AKY-2519 against B7-H3 in metastatic castration-resistant prostate cancer (NCT07581184). No efficacy results from a full publication are recorded here.
A small engineered protein binder against a tumour surface antigen carries a chelated radioisotope, usually an alpha emitter; its size is chosen for tumour penetration and retention with fast renal or hepatic clearance.
Query for this technology: (TITLE:"Miniprotein radioconjugates" OR ABSTRACT:"Miniprotein radioconjugates" OR TITLE:"miniprotein radiopharmaceuticals" OR ABSTRACT:"miniprotein radiopharmaceuticals" OR TITLE:"miniprotein radioligands" OR ABSTRACT:"miniprotein radioligands" OR TITLE:"miniprotein radioconjugate platform" OR ABSTRACT:"miniprotein radioconjugate platform") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Miniprotein radioconjugates, not a curated reading list.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Metastatic castration-resistant prostate cancer.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Aktis Oncology, Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Targeted alpha therapy, Radioligand therapy (beta emitters), Metastatic castration-resistant prostate cancer.
Shares Targeted alpha therapy, Radioligand therapy (beta emitters).
Shares Nectin-4, Bladder & urothelial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/